The Developmental Process of MK-3475 in Melanoma
Antoni Ribas, MD, PhD, discusses the development process of PD-1 antibody MK-3475 in melanoma.
Antoni Ribas, MD, PhD, professor of medicine, Jonsson Comprehensive Cancer Center, University of California, Los Angeles, discusses the development process of PD-1 antibody MK-3475 in melanoma.
Clinical Pearls
- MK-3475 has gone through phase I testing
- Physicians are eagerly awaiting data from a phase II clinical trial comparing chemotherapy to MK-3475 in patients who have previously received ipilimumab
- A trial studying two dosing regimens of MK-3475 compared to ipilimumab in frontline therapy for patients with metastatic melanoma is currently accruing
- MK-3475 is also being developed in other cancers, such as lung, bladder, and head and neck
Related Videos
Related Content
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024Article
In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More
